Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Buy” from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned a consensus recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $6.60.

A number of analysts have issued reports on TSHA shares. BMO Capital Markets started coverage on Taysha Gene Therapies in a research report on Thursday, June 27th. They issued an “outperform” rating and a $5.00 target price on the stock. JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $8.00 target price (up from $2.00) on shares of Taysha Gene Therapies in a research report on Tuesday, May 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Finally, Needham & Company LLC restated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, July 23rd.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA opened at $2.10 on Monday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.38 and a quick ratio of 3.38. Taysha Gene Therapies has a twelve month low of $0.66 and a twelve month high of $4.32. The company’s 50-day moving average price is $2.77 and its 200-day moving average price is $2.53.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $3.41 million for the quarter, compared to analysts’ expectations of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter in the prior year, the company posted ($0.28) earnings per share. On average, research analysts expect that Taysha Gene Therapies will post -0.41 earnings per share for the current year.

Insider Activity

In other news, major shareholder Paul B. Manning bought 1,333,333 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $2,999,999.25. Following the completion of the purchase, the insider now owns 1,333,333 shares in the company, valued at approximately $2,999,999.25. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in TSHA. Avoro Capital Advisors LLC increased its stake in Taysha Gene Therapies by 328.2% in the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after purchasing an additional 14,294,445 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Taysha Gene Therapies by 235.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock valued at $16,836,000 after buying an additional 3,738,616 shares during the last quarter. StemPoint Capital LP acquired a new stake in Taysha Gene Therapies during the 1st quarter worth $3,122,000. Bank of New York Mellon Corp purchased a new stake in Taysha Gene Therapies in the second quarter valued at $1,018,000. Finally, Monaco Asset Management SAM acquired a new position in Taysha Gene Therapies in the fourth quarter valued at $522,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.